HLS Therapeutics, Inc   Report issue

For profit Phase 4
Founded: Toronto Canada (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2020
NCT04412018
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

HLS Therapeutics, Inc

Active Ingredients

Drugs in Phase 4 Trials (1)

icosapent ethyl (vascepa) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiovascular Diseases (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 1